Edgewise Therapeutics to Present at the PPMD Annual Conference & the New Directions in Biology & Disease of Skeletal Muscle C...
June 22 2021 - 9:00AM
Business Wire
Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a clinical-stage
biopharmaceutical company focused on developing orally
bioavailable, small molecule therapies for rare muscle disorders,
today announced that the company will present at the 2021 PPMD
Annual Conference and the 2021 New Directions in Biology and
Disease of Skeletal Muscle Conference.
2021 PPMD Annual Conference
Presentation: An Introduction to Edgewise Therapeutics
Presenter: Alan Russell, Ph.D., Chief Scientific Officer,
Edgewise Therapeutics
Presentation: Development of a Novel Therapeutic for
Duchenne, Becker and other Muscular Dystrophies Date:
Wednesday, June 23, 2021 at 6:40 pm ET Presenter: Joanne
Donovan, M.D., Ph.D., Chief Medical Officer, Edgewise
Therapeutics
2021 New Directions in Biology and
Disease of Skeletal Muscle Conference Presentation:
Selective Inhibition of Fast Skeletal Muscle Myosin as a Novel
Therapeutic Strategy for Muscular Dystrophy Date: Monday,
June 28, 2021 at 12:10 p.m. ET Presenter: Alan Russell,
Ph.D., Chief Scientific Officer, Edgewise Therapeutics
The presentation at the New Directions conference describes the
potential of selective fast myosin inhibition to provide broad
protection of muscle in Duchenne muscular dystrophy (DMD) and
Becker muscular dystrophy (BMD).
The presentations will be available on the Edgewise website
after they are presented.
About Edgewise Therapeutics Edgewise Therapeutics is a
clinical-stage biopharmaceutical company focused on the discovery,
development and commercialization of innovative treatments for
severe, rare muscle disorders for which there is significant unmet
medical need. Guided by its holistic drug discovery approach to
targeting the muscle as an organ, Edgewise has combined its
foundational expertise in muscle biology and small molecule
engineering to build its proprietary, muscle focused drug discovery
platform. Edgewise’s platform utilizes custom-built high throughput
and translatable systems that measure integrated muscle function in
whole organ extracts to identify small molecule precision medicines
regulating key proteins in muscle tissue, initially focused on
addressing rare neuromuscular and cardiac diseases. To learn more,
go to: www.edgewisetx.com or follow us on LinkedIn.
Cautionary Note Regarding Forward-Looking Statements This
press release contains forward-looking statements as that term is
defined in Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. Statements in this
press release that are not purely historical are forward-looking
statements. Such forward-looking statements include, among other
things, statements regarding the potential of, and expectations
regarding Edgewise’s drug discovery platform and product candidates
including EDG-5506 and EDG-6289; statements about the expected
timing and results from Edgewise’s Phase 1 clinical trials for
EDG-5506; statements regarding Edgewise’s pipeline of product
candidates and programs; and statements by Edgewise’s chief
executive officer. Words such as “believes,” “anticipates,”
“plans,” “expects,” “intends,” “will,” “goal,” “potential” and
similar expressions are intended to identify forward-looking
statements. The forward-looking statements contained herein are
based upon Edgewise’s current expectations and involve assumptions
that may never materialize or may prove to be incorrect. Actual
results could differ materially from those projected in any
forward-looking statements due to numerous risks and uncertainties,
including but not limited to: risks associated with the process of
discovering, developing and commercializing drugs that are safe and
effective for use as human therapeutics and operating as an early
clinical stage company including the potential for Edgewise’s
product candidates to cause serious adverse events; Edgewise’s
ability to develop, initiate or complete preclinical studies and
clinical trials for, obtain approvals for and commercialize any of
its product candidates for muscular dystrophy patients or other
patient populations; the timing, progress and results of
preclinical studies and clinical trials for EDG-5506 and Edgewise’s
other product candidates in its EDG-6289, EDG-002 and EDG-003
programs; Edgewise’s ability to raise any additional funding it
will need to continue to pursue its business and product
development plans; negative impacts of the COVID-19 pandemic on
Edgewise’s operations, including preclinical and clinical trials;
the timing, scope and likelihood of regulatory filings and
approvals; Edgewise’s ability to develop a proprietary drug
discovery platform to build a pipeline of product candidates;
Edgewise’s manufacturing, commercialization and marketing
capabilities and strategy; the size of the market opportunity for
Edgewise’s product candidates; the loss of key scientific or
management personnel; competition in the industry in which Edgewise
operates; Edgewise’s reliance on third parties; Edgewise’s ability
to obtain and maintain intellectual property protection for its
product candidates; general economic and market conditions; and
other risks. Information regarding the foregoing and additional
risks may be found in the section entitled “Risk Factors” in
documents that Edgewise files from time to time with the Securities
and Exchange Commission (the “SEC”). These forward-looking
statements are made as of the date of this press release, and
Edgewise assumes no obligation to update the forward-looking
statements, or to update the reasons why actual results could
differ from those projected in the forward-looking statements,
except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210622005342/en/
Investors & Media Michael Carruthers Chief Financial
Officer ir@edgewisetx.com
Edgewise Therapeutics (NASDAQ:EWTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Edgewise Therapeutics (NASDAQ:EWTX)
Historical Stock Chart
From Apr 2023 to Apr 2024